Clinical Trial

Capecitabine and Cyclophosphamide (XC) as Maintenance Therapy for Advanced Breast Cancer

Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated September 11, 2025 (before its estimated June 2026 completion). Its status may not reflect the trial's current state.
Summary
To compare the efficacy and safety of capecitabine and cyclophosphamide (XC) versus physician's choice as maintenance therapy for patients with advanced breast cancer who achieved disease control after salvage treatment.
Protocol Amendment History 3 amendments
This ClinicalTrials.gov record has been amended 3 times since 2023-05-16; most recent amendment 2025-09-10.
Status change: Not Yet Recruiting → Recruiting 2023-11-18
Trial Details
NCT Number NCT05876065
Lead Sponsor Wenjin Yin
Conditions Advanced Breast Cancer
Enrollment 86 participants
Start Date 2023-06-01
Primary Completion 2026-06 (estimated)
Study Completion 2027-02 (estimated)
Updated on ClinicalTrials.gov 2025-09-11